Wistron Medical Technology

Wistron Medical Technology Corporation (WMT) operates as the dedicated medical technology arm of Wistron Corporation, a Fortune Global 500 electronics manufacturer listed on the Taiwan Stock Exchange (3231.TW). Established in 2016 with an initial investment of NT$2 billion, WMT focuses on developing intelligent rehabilitation robotics and providing ODM/EMS services for medical device companies worldwide.

Company Overview

WMT builds on its parent company’s extensive manufacturing expertise—Wistron ranks among the top 20 global ODM providers with over $34 billion in annual revenue—to produce medical-grade rehabilitation equipment. The company’s strategic partnership with Canadian biotechnology firm B-Temia Inc. has positioned WMT as a key player in the exoskeleton rehabilitation market across Asia.

In June 2017, Wistron became a major shareholder of B-Temia, gaining access to the company’s proprietary dermoskeleton technology. The following year, the two companies established B-Temia Asia in Singapore to accelerate market expansion across China, Japan, Hong Kong, and Southeast Asia.

WMT operates manufacturing facilities in Taiwan and mainland China. The Chongqing subsidiary, Wistron Medical Technical (Chongqing) Co., Ltd., established in Liangjiang New Area in 2016, serves as the primary production base for Class II and III medical devices targeting the Chinese market. In 2022, WMT expanded into Southeast Asia with the establishment of Wistron Medical Technology Malaysia, operating Keeogo rehabilitation training centers.

Core Products

Keeogo Lower Limb Exoskeleton

The Keeogo (启而走) represents WMT’s flagship rehabilitation product, developed through collaboration with B-Temia. Unlike traditional exoskeletons that control user movement, Keeogo employs dermoskeleton technology that follows and augments the wearer’s natural motion patterns. The system has received regulatory clearances in the United States (FDA 510(k)), European Union (CE Mark), China (NMPA), Taiwan (TFDA Class II), Japan, Malaysia, and Singapore.

Technical specifications include a total weight of 6.8 kg with battery (approximately half the weight of competing devices at 14+ kg), carbon fiber construction, AI-powered movement detection at hip and knee joints, and servo motors providing precise assistive force. The device supports rehabilitation for stroke, Parkinson’s disease, multiple sclerosis, and ankylosing spondylitis patients.

Technology & Innovation

WMT’s dermoskeleton approach differentiates itself from conventional exoskeleton systems through its sensing methodology. While Japanese competitors typically use sensor patches connected to the brain, requiring extensive signal processing, Keeogo detects movement intention through joint angle changes at the hip and knee. This approach enables faster response times and more precise AI-based movement prediction.

The rehabilitation platform incorporates gamified training modules including virtual bowling, golf, and Tai Chi exercises to enhance patient engagement during therapy sessions. Real-time monitoring via tablet applications tracks step length, balance metrics, and motor strength settings, building full rehabilitation profiles for each patient.

Market Presence

WMT has established Keeogo training centers in Malaysia, Singapore, and Japan, with the product distributed across Europe, Americas, and Asia-Pacific regions. The company initially focused on overseas markets before obtaining NMPA approval for the Chinese domestic market, where it now targets hospital-based stroke rehabilitation services.

The Keeogo gained international visibility when French para-athlete Géraud Paillot, who has lived with multiple sclerosis for 20 years, wore the device during the 2024 Paris Olympics torch relay in Saint-Malo, France. Following rehabilitation training with the exoskeleton, Paillot regained the ability to walk and run independently.

Key Milestones

• 2016: Wistron Medical Technology established in Taiwan; Chongqing manufacturing facility opened
• 2017: Wistron becomes major shareholder of B-Temia Inc.
• 2018: B-Temia Asia joint venture established in Singapore
• 2020: Keeogo receives TFDA Class II certification and FDA 510(k) clearance
• 2022: WMT Malaysia subsidiary established
• 2024: Keeogo featured at Paris Olympics torch relay; NMPA approval obtained for Chinese market

Frequently Asked Questions

What is the relationship between Wistron Medical Technology and Wistron Corporation?

Wistron Medical Technology is a wholly-owned subsidiary of Wistron Corporation (3231.TW), a Fortune Global 500 company. The parent company provides manufacturing expertise and financial backing, while WMT focuses exclusively on medical device development and rehabilitation robotics.

Where is the Keeogo exoskeleton manufactured?

Keeogo production takes place primarily at Wistron Medical Technical (Chongqing) Co., Ltd. in Liangjiang New Area, China. The facility has operated since 2016 as WMT’s medical device manufacturing base for the Asia market.

What conditions can Keeogo help treat?

Keeogo is indicated for patients with lower limb mobility impairments resulting from stroke, Parkinson’s disease, multiple sclerosis, ankylosing spondylitis, and other neurological conditions affecting gait and lower body strength.